A5056775213- Inflammatory Bowel Disease
- Microscopic Colitis
- Diverticular Disease and Complications
- Anorectal Disease Treatments and Outcomes
- Colorectal Cancer Surgical Treatments
- Colorectal and Anal Carcinomas
- Autoimmune and Inflammatory Disorders
- Celiac Disease Research and Management
- Gastrointestinal disorders and treatments
- Hidradenitis Suppurativa and Treatments
- Diverse academic and cultural studies
- Gastrointestinal motility and disorders
- Diagnosis and treatment of tuberculosis
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Genetic factors in colorectal cancer
- Gastric Cancer Management and Outcomes
- Eosinophilic Esophagitis
- Congenital gastrointestinal and neural anomalies
- Mesenchymal stem cell research
- IgG4-Related and Inflammatory Diseases
- Immunodeficiency and Autoimmune Disorders
- Liver Diseases and Immunity
- Soft tissue tumor case studies
- Appendicitis Diagnosis and Management
- Autoimmune and Inflammatory Disorders Research
University of Bologna
2013-2024
Policlinico S.Orsola-Malpighi
2003-2024
Azienda USL di Bologna
2021-2023
Institute of Clinical and Experimental Medicine
2012
University of Miskolc
2012
Cleveland Foundation
2002
Cleveland Clinic
2000-2002
University of Perugia
1994
Medicina
1993
Abstract This paper is the second in a series of two publications relating to European Crohn’s and Colitis Organisation [ECCO] evidence-based consensus on diagnosis management disease [CD] concerns surgical CD as well special situations including perianal extraintestinal manifestations. Diagnostic approaches medical this ECCO Consensus are covered first [Gomollon et al. JCC 2016].
SUMMARY Background Pouchitis is the major long‐term complication after ileal‐pouch nal anastomosis for ulcerative colitis. Ten to 15% of patients develop a chronic pouchitis, either treatment responsive or refractory. Aim To evaluate efficacy oral budesonide in inducing remission and improving quality life with refractory pouchitis. Methods Twenty consecutive active not responding 1 month antibiotic were treated controlled ileal release 9 mg/day 8 weeks. Symptomatic, endoscopic histological...
PURPOSE: Perianal disease is a serious complication of Crohn's and its surgical management still controversial. It has been suggested that the local injection infliximab resulted in some potential benefit. This pilot study analyzed feasibility safety such therapy selected patients with severe perianal disease. METHODS: The included 15 complex which sepsis was not controllable using medical therapy. Among them, four had previously undergone intravenous infusion no significant response, nine...
The study exploited autologous microfragmented fat to treat refractory complex Crohn’s perianal fistula, obtaining 66.7% of combined remission at 6 months in patients already treated without success using biosurgical approaches and multiple repair surgeries following the failure biological therapy.
The overall risk of permanent stoma was determined in patients with extensive Crohn's colitis. An attempt made to analyse whether biological drugs have modified the surgical approach anorectal involvement.In all, 233 disease colitis operated on between 1995 and 2010 were reviewed retrospectively. Fifty-one treated before 2002 (prebiological era) 182 after (biological era). relationship use immunosuppressors, drugs, presence perianal stenosis rate formation.In prebiological era 23 (45.1%)...
Pouchitis is the major long-term complication after ileal-pouch anal-anastomosis for ulcerative colitis. Ten to 15% of patients develop chronic pouchitis, either treatment responsive or refractory.To evaluate efficacy oral beclomethasone dipropionate in inducing remission and improving quality life with refractory pouchitis.Ten consecutive active not responding 1-month antibiotic treatment, were treated 10 mg⁄day 8 weeks. Clinical, endoscopic histological evaluations undertaken before...
PURPOSE: Terminal ileitis is the most frequent presentation of Crohn's disease. Resection terminal ileum and cecum with ileocolic anastomosis has always been considered “gold standard” in surgical treatment this condition. This study illustrates an alternative technique referred to as “side-to-side enterocolic anastomosis.” METHODS: It consists a longitudinal section starting 1 2 cm away from beginning stricture continued for similar length on ascending colon. A side-to-side then fashioned,...
Conservative surgery has become the treatment of choice for diffuse jejunoileal Crohn's Disease. Previous research described a conservative approach both multiple strictures located in close proximity to each other and long stenoses. The side-to-side enteroenteric anastomosis gained popularity lead nonresectional even those patients who, until now, were considered suitable only resection. This technique however, presents our hands some disadvantages represented mainly by early restenosis at...
This study was designed to assess clinical and pathologic features of duodenal Crohn's disease (CD) address its management according different patterns disease.Twelve cases involvement in CD are reported out 336 patients treated between 1978 1993. They represent 3.6 percent all cases. Three had a fistula, nine an intrinsic lesion. The fistula manifestation recurrent involving ileocolic anastomosis the third portion duodenum.Treatment consisted resection fistula's source primary closure...
Abstract Introduction Due to their immunomodulatory properties, mesenchymal stromal cells (MSCs) have been used for auto-immune disease treatment. Crohn (CD) and ulcerative colitis are two major inflammatory bowel diseases (IBDs), resulting from pathological immune responses environmental or microbial antigens. Preclinical clinical studies suggested that MSC-based cellular therapy hold promising potential IBD However, open issues include the selection of proper cell dose, source optimal...
As an alternative to resection, strictureplasty may allow for preservation of intestinal length and avoidance short-bowel syndrome in patients with diffuse Crohn's jejunoileitis. However, the long-term durability procedure its safety have not been confirmed. The purpose this study was report our experience jejunoileitis.Between 1984 1999, 123 underwent a laparotomy that included index Patient history, operative details, postoperative morbidities were obtained by chart review. Nineteen (15...
The recent introduction of infliximab, a chimeric monoclonal antibody against tumor necrosis factor-α, has greatly modified the treatment Crohn's disease (CD).Data from literature show encouraging results after intravenous infusion both for closure intestinal or perianal fistulas and induction maintenance remission in patients with moderate to severe unresponsive other treatments.However, some contraindications such as fibrostenosing CD sepsis have been identified.In addition, data on...